AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models

INTRODUCTION: Epidermal growth factor receptor (EGFR) overexpression has been associated with prognostic and predictive value in inflammatory breast cancer (IBC). Epidermal growth factor receptor 2 (HER2) overexpression is observed at a higher rate in IBC compared with noninflammatory breast cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Zhaomei, Klinowska, Teresa, Dong, Xiaoshen, Foster, Emily, Womack, Chris, Fernandez, Sandra V, Cristofanilli, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061513/
https://www.ncbi.nlm.nih.gov/pubmed/24886365
http://dx.doi.org/10.1186/1756-9966-33-47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061513/
https://www.ncbi.nlm.nih.gov/pubmed/24886365
http://dx.doi.org/10.1186/1756-9966-33-47

Ejemplares similares